ZEPZELCA lurbinectedin 4 mg powder for solution for infusion 1 vial per carton অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

zepzelca lurbinectedin 4 mg powder for solution for infusion 1 vial per carton

specialised therapeutics pharma pty ltd - lurbinectedin, quantity: 4 mg - injection, powder for - excipient ingredients: sucrose; sodium hydroxide; (s)-lactic acid - zepzelca is indicated for the treatment of patients with metastatic small cell lung cancer (sclc) that has progressed on or after prior platinum-containing therapy. this indication was approved via the provisional approval pathway, based on objective response rate and duration of response in a single arm trial. continued approval for this indication depends on verification and description of clinical benefit in a confirmatory trial.